Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer (Q28271324)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer |
scientific article |
Statements
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer (English)
Rafael G Amado
Michael Wolf
Daniel J Freeman
Todd Juan
Robert Sikorski
Sid Suggs
Robert Radinsky
Scott D Patterson
David D Chang
Identifiers
2 references
2 references